YOLFTbeta
CellBion Co., Ltd.

CellBion Co., Ltd.

308430 · KQ · Healthcare / Biotechnology

12,200.00KRW+30.00 (+0.25%)

Price History

Full chart

Market Stats

Previous Close12,170.00
Open12,000.00
Day Range11,910.00 – 12,450.00
52-Week Range9,930.00 – 42,200.00
Volume14.29K
Market Cap187.21B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg13,316.20
200-Day Avg22,312.00

About

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. CellBion Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Kweon Kim Ph.D.
  • Employees55
  • Headquarters103, Daehak-ro, Seoul, South Korea, 03080, Korea
  • Websitehttps://www.cellbion.co.kr

Leadership

  • Mr. Kweon Kim Ph.D.President, CEO & Director
  • Mr. Jae-Min JungChief Scientific Officer
  • Sung Ho LeeManaging Director · b. 1960
  • Jae-Min ParkVP & Inside Director · b. 1968

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue916.88M1.76B1.47B2.29B1.95B
Growth (%)-+92.27%-16.54%+55.64%-15.05%
Cost of Revenue1.04B1.55B1.16B1.32B1.86B
Gross Profit-118.36M207.90M313.52M967.40M88.63M
Gross Margin-12.91%11.79%21.31%42.25%4.56%
Operating Expense4.43B5.35B4.09B8.10B8.33B
Operating Income-4.55B-5.14B-3.78B-7.14B-8.24B
Operating Margin-496.28%-291.52%-256.91%-311.67%-423.87%
EBITDA--5.26B-2.87B-6.51B-6.66B
EBITDA Margin--298.47%-195.41%-284.36%-342.30%
Net Income-4.78B-6.38B-3.63B-7.27B-7.57B
Net Income Margin-521.08%-362.02%-246.92%-317.32%-389.37%
R&D2.36B3.02B3.43B5.30B4.97B
R&D as % of Total Revenue257.13%171.27%232.86%231.26%255.65%
Interest Expense276.80M352.51M140.18M129.87M137.03M
Interest Expense % of Total Revenue30.19%20.00%9.53%5.67%7.05%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.85B10.04B11.35B34.41B35.19B
Total Liabilities5.38B7.30B3.85B4.83B12.41B
Total Equity8.47B2.74B7.50B29.58B22.79B
Cash807.12M746.89K480.79K485.79K1.96B
Net Debt593.45M425.41M-244.67M-

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.49B-4.64B-3.94B-4.78B-5.55B
Investing Cash Flow-5.33B-2.54B-23.83B-
Financing Cash Flow--277.54M6.00B28.95B-
Capital Expenditure247.65M525.43M432.62M166.93M1.68B
Free Cash Flow-3.74B-5.17B-4.37B-4.94B-7.22B
FCF to OCF107.09%111.32%110.99%103.49%130.28%

Earnings

Report DateMar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------
EPS Actual-111.49-194.84-142.76-188.87-186.87-165.40
Surprise------
Timing------

Key Statistics & Ratios

Market Cap187.21B
Enterprise Value134.73B
Trailing P/E0.00
Forward P/E0.00
Price / Sales87.25
Price / Book5.22
Revenue (TTM)2.15B
Gross Profit (TTM)-122.13M
EBITDA-8.95B
Profit Margin361.16%
Operating Margin-559.61%
Return on Equity24.79%
Return on Assets-10.41%
Shares Outstanding12.83M
Shares Float8.20M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%